Related Experiment Videos
Temozolomide in combination with other cytotoxic agents
1Department of Neurosurgery, University of California, San Francisco, CA 94143-0372, USA.
Seminars in Oncology
|September 11, 2001
Summary
Temozolomide shows promise in combination therapies for brain tumors. Combining it with carmustine or irinotecan may improve efficacy, with specific sequencing impacting toxicity and effectiveness.
Area of Science:
- Oncology
- Pharmacology
- Neuro-oncology
Background:
- Temozolomide exhibits broad-spectrum antitumor activity and crosses the blood-brain barrier.
- Its favorable safety profile and oral formulation make it suitable for combination therapies.
- Temozolomide can overcome resistance to nitrosoureas.
Purpose of the Study:
- To evaluate the efficacy and safety of temozolomide in combination with other chemotherapeutic agents.
- To explore the potential of temozolomide-based combinations for treating solid tumors, particularly malignant glioma.
- To investigate sequence-dependent effects and optimal dosing schedules for combination therapies.
Main Methods:
- Preclinical studies and Phase I clinical trials were conducted.
- Combination therapies involving temozolomide with carmustine and irinotecan (CPT-11) were examined.
- Sequence-dependent toxicity and efficacy were assessed.
Main Results:
- Temozolomide combined with carmustine demonstrated additive or synergistic activity against solid tumors, including malignant glioma.
- Giving carmustine before temozolomide resulted in lower toxicity and a higher maximum tolerated dose.
- Temozolomide followed by irinotecan (CPT-11) was more effective than either agent alone.
Conclusions:
- Temozolomide is a valuable agent for combination chemotherapy in oncology.
- Optimizing the schedule of temozolomide with carmustine or irinotecan is crucial for maximizing therapeutic benefit.
- Further research is needed to determine the optimal schedules for these combination therapies.